Literature DB >> 6859018

Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis.

I C Danielides, M Constantoulakis, G K Daikos.   

Abstract

Hepatitis developed in two patients treated with high doses (1000 mg/day) of isoniazid for severe tuberculous meningitis. Isoniazid was discontinued and later readministered in gradually increasing intrathecal and subsequently oral doses, up to the final dose of 400 mg/day. Transaminases remained normal, during 12 months on this dose, suggesting dose dependence of hepatotoxicity or a metabolic adaptation to the injury. Continued isoniazid treatment can be important in similar cases and it may become possible, if oral or intrathecal doses significantly lower than the initial hepatotoxic ones, are used.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6859018

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.

Authors:  Paul H Hayashi; Robert J Fontana; Naga P Chalasani; Andrew A Stolz; Jay A Talwalkar; Victor J Navarro; William M Lee; Timothy J Davern; David E Kleiner; Jiezhun Gu; Jay H Hoofnagle
Journal:  Clin Gastroenterol Hepatol       Date:  2015-02-24       Impact factor: 11.382

2.  Intrathecal therapy for tuberculous meningitis: propensity-matched cohort study.

Authors:  Kunyi Li; Lijun Wang; Lan Wen; Jian Wang; Maolin Li
Journal:  Neurol Sci       Date:  2021-10-27       Impact factor: 3.307

3.  Intrathecal Isoniazid for Refractory Tuberculous Meningitis with Cerebral Infarction.

Authors:  Yuko Nakatani; Yutaka Suto; Kazuki Fukuma; Mika Yamawaki; Ryoichi Sakata; Shotaro Takahashi; Hiroyuki Nakayasu; Kenji Nakashima
Journal:  Intern Med       Date:  2017-04-15       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.